In Brief: InControl
This article was originally published in The Gray Sheet
Executive Summary
InControl: Announces first implantation of its Metrix 3020 atrial defibrillator at the Universitair Ziekenhuis Gent in Ghent, Belgium. The 3020 incorporates "a new waveform which allows the device to deliver up to a maximum of six joules of energy," compared to the three joule capability of the firm's first-generation Metrix 3000. Early clinical study data comparing the two waveforms have demonstrated that the 3020 waveform "results in improved patient tolerance at similar defibrillation thresholds," InControl states. An investigational device exemption for the 3020 was submitted to FDA the week of Aug. 26...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.